Andere talen ABVC BioPharma, Inc.

Aandelen

ABVC

US00091F3047

Geschatte realtime Cboe BZX Andere beurzen 18:47:05 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,09 ^USD	-12,80%		-27,03%	-6,90%

10/04	ABVC BioPharma, Inc., BioLite, Inc. en Rgene Corporation gaan Term Sheet aan met OncoX BioPharma, Inc.	CI
26/03	ABVC BioPharma, Inc. en BioFirst Corporation gaan een wereldwijde licentieovereenkomst aan met ForSeeCon Eye Corporation	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	18/04
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	17/04
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	10/04
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	10/04
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	26/03
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	26/03
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	21/03
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	19/03
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	14/03
ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	14/03
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
ABVC BioPharma Signs Licensing Deal With Senior Paradise	15/02
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	15/02
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	15/02
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	12/02
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	08/02
ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC	17/01
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	08/01
Top Premarket Decliners	04/01
Sector Update: Health Care Stocks Mixed Late Afternoon	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ABVC BioPharma, Inc.

Aandelen

ABVC

US00091F3047

Andere talen

Filters